Table 42Summary of included studies. Comparison 41. Augmenting with anticonvulsant versus lithium

StudyPopulationInterventionComparisonDetails of inadequate response/treatment resistanceComments

Schindler 2007

RCT

Germany

N=34

Mean age (years): 47.7

Gender (% female): 50

Ethnicity (% BME): NR

Baseline severity: HAMD 22.1 (More severe)

Lamotrigine 25-250mg/day (mean final dose 152.94 mg/day) + any antidepressantLithium target plasma level 0.6–0.8mmol/l (mean final plasma level 0.71mmol/l) + any antidepressantTRD: Inadequate response (<50% reduction of initial HAMD) to at least 2 trials of different classes of antidepressants for a duration of at least 6 weeks

Treatment length (weeks): 8

Outcomes:

  • Depression symptomatology endpoint
  • Depression symptomatology change score
  • Remission
  • Response
  • Discontinuation due to any reason
  • Discontinuation due to side effects

BME: black and minority ethnic; HAMD: Hamilton depression scale; NR: not reported; RCT: randomised controlled trial; TRD: treatment-resistant depression

From: Further-line treatment

Cover of Further-line treatment
Further-line treatment: Depression in adults: Evidence review D.
NICE Guideline, No. 222.
Copyright © NICE 2022.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.